The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls

Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma

(2009) Timothy S. Fenske et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma

(2009) Navneet S. Majhail et al.   BRITISH JOURNAL OF HAEMATOLOGY

Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide

(2009) Robert M. Dean et al.   BRITISH JOURNAL OF HAEMATOLOGY

Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma

(2008) L Damon et al.   BONE MARROW TRANSPLANTATION

Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma

(2008) Kai Fu et al.   JOURNAL OF CLINICAL ONCOLOGY

Late Congestive Heart Failure After Hematopoietic Cell Transplantation

(2008) Saro H. Armenian et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

(2007) E. Vellenga et al.   BLOOD

Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation

(2007) P. Fu et al.   Contemporary Clinical Trials